Government-Owned Inventions; Availability for Licensing, 42090 [2023-13792]
Download as PDF
42090
Federal Register / Vol. 88, No. 124 / Thursday, June 29, 2023 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
pharmaceutical compositions, and
methods of use.
National Institutes of Health
Potential Commercial Applications
•
•
•
•
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Development Stage
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. to achieve
expeditious commercialization of
results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive, Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
Michael Shmilovich; shmilovm@
nih.gov; telephone: 301–435–5019. A
signed Confidential Disclosure
Agreement may be required to receive
any unpublished information.
SUPPLEMENTARY INFORMATION:
Technology description follows.
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
Cannabinoid Receptor Modulating
Compounds
Available for licensing and
commercial development are potentially
therapeutic compounds for metabolic,
inflammatory and fibrotic disorders.
The filed patent applications includes
extensive descriptions of the exemplary
molecules and their various
constituents. The cannabinoid receptor
mediating compounds can be neutral
antagonists. A CB1 inverse agonist is a
drug that on its own produces an effect
opposite to that of a CB1 agonist, and is
also able to block the effect of a CB1
agonist. In contrast, a CB1 neutral
antagonist can only do the latter (i.e.,
blocking the effect of a CB1 agonist), but
has no effect on its own. CB1 inverse
agonism is usually documented by the
ability of a drug to decrease GTPgS
binding and/or to increase adenylate
cyclase activity. The compounds may
show functional bias for GTPgS or bArrestin or activity for both GTPgS and
b-Arrestin. Secondary targets could
include, but not limited to, the enzyme
inducible nitric oxide synthase (iNOS)
or adenosine monophosphate kinase
(AMPK), as suggested by findings that
inhibition of iNOS or activation of
AMPK improves insulin resistance, and
reduces fibrosis and inflammation. The
rights pursued claim compounds,
VerDate Sep<11>2014
17:21 Jun 28, 2023
Pharmaceuticals
Cancer therapy
Anti-fibrotic therapy
Inflammatory and autoimmune
disease
Jkt 259001
• Early stage
Inventors: Malliga R. Iyer, Ph.D.;
Pinaki Bhattacharjee, Ph.D.; Resat Cinar,
PharmD, MBA; George Kunos, M.D.,
Ph.D.; Szabolcs Dvoracsko Ph.D., (all of
NIAAA).
Intellectual Property: HHS Reference
No. E–189–2021–0; U.S. Provisional
Patent Application No. 63/319,642 filed
March 14, 2022; International Patent
Application PCT/U2023/014846 filed
March 8, 2023.
Licensing Contact: Michael
Shmilovich; 301–435–5019;
michael.shmilovich@nih.gov.
This notice is in accordance with 35
U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development.
Dated: June 23, 2023.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2023–13792 Filed 6–28–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Clinical Trials SEP (UG3, U24).
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Date: July 27, 2023.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Zhihong Shan, Ph.D., MD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 205–J,
Bethesda, MD 20892, (301) 827–7085,
zhihong.shan@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: June 26, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–13854 Filed 6–28–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Project: SAMHSA Generic Clearance
for Grant Program Monitoring
Activities
To carry out OMB Circular A–102 1
and 2 CFR part 215.51,2 SAMHSA must
collect grant program information
necessary to ensure compliance with
Federal and programmatic
requirements. The Generic Clearance for
Grant Program Monitoring Activities
allows SAMHSA to collect standardized
information from its grant recipients
necessary to perform agency program
oversight activities such as monitoring
progress on recipient activities and
determining and responding to
1 Circular A–102: https://www.whitehouse.gov/
wp-content/uploads/legacy_drupal_files/omb/
circulars/A102/a102.pdf.
2 2 CFR part 215.51: https://www.govinfo.gov/
content/pkg/CFR-2012-title2-vol1/pdf/CFR-2012title2-vol1-subtitleA.pdf.
E:\FR\FM\29JNN1.SGM
29JNN1
Agencies
[Federal Register Volume 88, Number 124 (Thursday, June 29, 2023)]
[Notices]
[Page 42090]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-13792]
[[Page 42090]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. to achieve
expeditious commercialization of results of federally-funded research
and development.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the indicated licensing contact at the National Heart,
Lung, and Blood, Office of Technology Transfer and Development Office
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda,
MD 20892-2479; Michael Shmilovich; [email protected]; telephone: 301-
435-5019. A signed Confidential Disclosure Agreement may be required to
receive any unpublished information.
SUPPLEMENTARY INFORMATION: Technology description follows.
Cannabinoid Receptor Modulating Compounds
Available for licensing and commercial development are potentially
therapeutic compounds for metabolic, inflammatory and fibrotic
disorders. The filed patent applications includes extensive
descriptions of the exemplary molecules and their various constituents.
The cannabinoid receptor mediating compounds can be neutral
antagonists. A CB1 inverse agonist is a drug that on its own
produces an effect opposite to that of a CB1 agonist, and is
also able to block the effect of a CB1 agonist. In contrast,
a CB1 neutral antagonist can only do the latter (i.e.,
blocking the effect of a CB1 agonist), but has no effect on
its own. CB1 inverse agonism is usually documented by the
ability of a drug to decrease GTP[gamma]S binding and/or to increase
adenylate cyclase activity. The compounds may show functional bias for
GTP[gamma]S or [beta]-Arrestin or activity for both GTP[gamma]S and
[beta]-Arrestin. Secondary targets could include, but not limited to,
the enzyme inducible nitric oxide synthase (iNOS) or adenosine
monophosphate kinase (AMPK), as suggested by findings that inhibition
of iNOS or activation of AMPK improves insulin resistance, and reduces
fibrosis and inflammation. The rights pursued claim compounds,
pharmaceutical compositions, and methods of use.
Potential Commercial Applications
Pharmaceuticals
Cancer therapy
Anti-fibrotic therapy
Inflammatory and autoimmune disease
Development Stage
Early stage
Inventors: Malliga R. Iyer, Ph.D.; Pinaki Bhattacharjee, Ph.D.;
Resat Cinar, PharmD, MBA; George Kunos, M.D., Ph.D.; Szabolcs Dvoracsko
Ph.D., (all of NIAAA).
Intellectual Property: HHS Reference No. E-189-2021-0; U.S.
Provisional Patent Application No. 63/319,642 filed March 14, 2022;
International Patent Application PCT/U2023/014846 filed March 8, 2023.
Licensing Contact: Michael Shmilovich; 301-435-5019;
[email protected].
This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404
to achieve expeditious commercialization of results of federally-funded
research and development.
Dated: June 23, 2023.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2023-13792 Filed 6-28-23; 8:45 am]
BILLING CODE 4140-01-P